Tuesday, May 26, 2026
← Back to archivePolicy
Policy•STAT News•May 26, 2026
Opinion: The innovation trap: How pharma weaponizes a word to extend monopolies
background ▾
- •AbbVie used patent thicketing on Humira (136 patents on a single molecule across multiple indications) to block generic entry for 7 years after original patent expiration, generating $114 billion in monopoly revenues during that extended period
- •McKinsey consulting documentation obtained by House Committee revealed AbbVie received strategic advice on building product extensions and patent strategies specifically designed to block competition rather than support genuine innovation
- •This case exemplifies how pharma companies weaponize 'innovation' terminology to justify patent multiplication on existing molecules for new indications, establishing a policy precedent relevant to ongoing drug pricing reform debates in Congress
AbbVieMcKinseyHumiraadalimumab
→ Read original articlePolicy•KFF•May 26, 2026
AI at Scale: Does It Deliver?
background ▾
- •HCA Healthcare operates at unprecedented scale for private sector AI deployment (190 hospitals, 47 million annual patient encounters), providing real-world insight into enterprise-wide implementation challenges
HCA Healthcare
→ Read original articlePolicy•Fierce Pharma•May 26, 2026
Novartis, AbbVie plan summer layoffs on opposite coasts
background ▾
- •Two major pharma companies executing simultaneous but geographically distinct layoffs, suggesting potential sector-wide cost pressures
NovartisAbbVie
→ Read original articlePolicy•STAT News•May 26, 2026
Opinion: The Ebola outbreak will lead to devastating violence against women and girls
background ▾
- •This is an opinion/advocacy piece rather than pharmaceutical industry news—it contains no drug development, clinical trial, regulatory, or commercial market access information relevant to pharma professionals
Policy•STAT News•May 26, 2026
Opinion: 8 former CDC directors: Reform PEPFAR, don’t dismantle it
background ▾
- •State Department has frozen funding for 105 CDC cooperative agreements supporting HIV treatment for 8.1 million people, with potential closure of 18 CDC global outposts by year-end and 85% of global CDC presence within two years
- •Eight former CDC directors warn that rapid PEPFAR restructuring without transition planning risks dismantling critical disease surveillance infrastructure that protects Americans from overseas outbreaks, citing recent USAID dismantling as a cautionary example
- •Watch for: Congressional response, State Department clarification of transition timeline, impact on HIV treatment continuity in partner countries, and whether African nations can realistically absorb CDC functions without interim support structure
Market Access
Market Access•Fierce Pharma•May 26, 2026
Real-World Evidence in the AI Era: What You Can Unlock Depends on What You Build On
background ▾
- •Data quality, not algorithmic sophistication, is the limiting factor for AI-driven real-world evidence systems in pharma
Market Access•Endpoints News•May 26, 2026
Adtech company Swoop buys pharmacy startup NimbleRx
background ▾
- •Swoop's acquisition of NimbleRx signals consolidation among digital pharmacy and adtech startups in the healthcare space
SwoopNimbleRx
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•May 25, 2026
Lilly preps for ph. 2 launch after Verve gene editor cuts cholesterol on par with PCSK9 inhibitors
background ▾
- •VERVE-102 achieved 62% LDL-C reduction sustained for 18 months, comparable to or exceeding PCSK9 inhibitor efficacy in pivotal trials, clearing the >50% efficacy bar for cardiovascular gene editors
- •Switched delivery formulation (GalNac-containing lipid nanoparticle) appears to have resolved prior liver toxicity issues observed in Verve's first PCSK9 base editor, suggesting improved safety profile
- •Watch for phase 2 initiation timing, dose escalation decisions, and long-term durability data; key uncertainty remains whether one-time gene editing will be positioned for broad use or narrowly in younger HeFH patients with decades of life ahead
Eli LillyVerve TherapeuticsAmgenVERVE-102Repatha
→ Read original articleClinical Trials•Fierce Pharma•May 26, 2026
Eliminating KRAS: Why targeted protein degraders could redefine what’s possible in cancer
background ▾
- •Targeted protein degraders offer a novel mechanism to address KRAS—a previously difficult-to-target driver mutation affecting multiple cancer types—potentially overcoming limitations of existing small-molecule inhibitors
- •Astellas is actively developing PROTAC-based approaches in oncology, signaling serious industry investment in this degradation technology platform
Astellas
→ Read original articleClinical Trials•Fierce Biotech•May 22, 2026
Biogen axes Denali-partnered Parkinson’s prospect after phase 2 flop
background ▾
- •Target engagement achieved but no efficacy signal: robust LRRK2 inhibition and biomarker modulation failed to translate into clinical benefit, challenging the LRRK2 hypothesis in idiopathic Parkinson's and questioning whether kinase inhibition alone is sufficient.
- •Biogen's second LRRK2 failure in 12 months undermines the target class, following termination of an Ionis antisense program in 2023, though other competitors (Neuron23, Arvinas) continue pursuing LRRK2.
- •Genetic subpopulation strategy remains: Denali's ongoing phase 2a in LRRK2-mutation carriers (4% of familial cases) will be critical to determining whether genetic enrichment can rescue the program or if the entire target class is compromised for Parkinson's.
BiogenDenali TherapeuticsIonis PharmaceuticalsBIIB122DNL151
→ Read original articleClinical Trials•Endpoints News•May 22, 2026
Tender offer for Recordati; Sobi's gout drug passes Phase 3 test
background ▾
- •Sobi's gout drug achieved Phase 3 efficacy targets, de-risking advancement toward regulatory submission and potential market entry
- •Tender offer for Recordati by major investment firms indicates consolidation interest in established pharmaceutical companies with diversified portfolios
- •Outcomes for Immunovant and Retro Biosciences mentioned but details absent—requires follow-up on their respective clinical/commercial developments
Sobi (Swedish Orphan Biopharma)RecordatiCVC Capital PartnersSobi gout drug (INN/brand name not specified)
→ Read original articleClinical Trials•Fierce Biotech•May 22, 2026
BioAge CEO talks NLRP3 and ‘pipeline in a pill’ ambitions
background ▾
- •BioAge Labs is advancing BGE-102, an oral NLRP3 inhibitor, with claimed multi-indication potential across cardiovascular, ocular, and CNS diseases through aging-focused inflammation targets
BioAge LabsBGE-102
→ Read original article